Quick Answer
Dyne Therapeutics, Inc. reported Cash and Equivalents of $893.37 million for fiscal year 2025.
Dyne Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $893.37M | +105.2% |
| 2024 | $435.45M | +258.0% |
| 2023 | $121.63M | -29.3% |
| 2022 | $172.15M | -14.3% |
| 2021 | $200.82M | -33.2% |
| 2020 | $300.85M | +1956.1% |
| 2019 | $14.63M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $573.61M | +7.8% | +18.3% |
| June 30, 2025 | $485.04M | -20.2% | +2.7% |
| March 31, 2025 | $472.25M | +73.6% | +8.5% |
| December 31, 2024 | $435.45M | +258.0% | -18.2% |
| September 30, 2024 | $532.16M | +308.5% | -12.5% |
| June 30, 2024 | $608.20M | +262.9% | +123.6% |
| March 31, 2024 | $272.04M | +50.2% | +123.7% |
| December 31, 2023 | $121.63M | -29.3% | -6.6% |
- Dyne Therapeutics, Inc. showed an increase of +105.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Dyne Therapeutics, Inc.’s cash and equivalents has grown by 6005.6% (from $14.63 million to $893.37 million).
- The most recent figure is from Dyne Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: